Abstracts tagged "B-Cell Targets"

Abstract Number: 2048 • ACR Convergence 2020
Comparison of Two Rituximab Regimens for Induction of Remission in Antineutrophil Cytoplasm Antibody-associated Vasculitis: Systematic Review and Meta-analysis
Valerie Benard¹, Cynthia Farhat², Melissa Zarandi-Nowroozi², Madeleine Durand³, Christian Pagnoux⁴, Pierre Charles⁵, Xavier Puechal⁶, Loïc Guillevin⁷ and Jean-Paul Makhzoum¹, ¹Vasculitis Clinic, Canadian Network for Research on Vasculitides (CanVasc), Department of Internal Medicine, Hopital du Sacre-Coeur de Montreal, University of Montreal, Montreal, QC, Canada, ²Department of Medecine, University of Montreal, Montreal, QC, Canada, ³Department of Internal Medicine, Centre Hospitalier de l’Universite de Montreal (CHUM) and Centre de Recherche du Centre Hospitalier de l’Universite de Montreal (CRCHUM), Montreal, QC, Canada, ⁴Vasculitis Clinic, Canadian Network for Research on Vasculitides (CanVasc), Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Department of Internal Medicine, Institut Mutualiste Montsouris, Paris, France, ⁶National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University, Paris, France, ⁷Department of Internal Medecine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University, Paris, France
Background/Purpose: Organ or life-threatening granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), two of the antineutrophil cytoplasm antibody-associated vasculitis (AAV), are treated with cyclophosphamide or…
Abstract Number: 0775 • ACR Convergence 2020
T and B Cell Responses to Common Tenascin-C Peptides in RA
JING Song¹, Anja Schwenzer², Sara Turcinov³, Alicia Wong², Cliff Rims¹, Lorena Rodriguez Martinez², David Arribas-Layton⁴, Christina Gerstner⁵, Virginia Muir⁶, Jeffrey Carlin⁷, Kim Midwood², Vivianne Malmström⁸, Eddie James¹ and Jane Buckner¹, ¹Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, ²Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³Division of Rheumatology, Department of Medicine,Center for Molecular Medicine, Institutet, Stockholm, Sweden, ⁴Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, ⁵Division of Rheumatology, Department of Medicine,Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁶Center for Systems Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁷Department of Rheumatology, Virginia Mason Medical Center, Seattle, WA, ⁸Karolinska Institutet, Stockholm, Stockholms Lan, Sweden
Background/Purpose: Although autoreactive CD4+ T cell and antibody responses against citrullinated antigens are known to contribute to loss of immune tolerance in rheumatoid arthritis (RA),…
Abstract Number: 0860 • ACR Convergence 2020
PREVAIL 1: A Multiple Ascending Dose Study in Normal Healthy Volunteers of PRV-3279, a Novel Bispecific DART Molecule Targeting CD32B and CD79B on B Cells, with Potential for Treatment of SLE
Paul Dunford¹, Gail Comer¹, Ralph Raymond¹, Donald Jung¹, Paul Moore², Francisco Leon¹ and Joan Merrill³, ¹Provention Bio, Oldwick, NJ, ²MacroGenics, Rockville, MD, ³Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: B-cell targeted therapeutics have proven efficacious in the treatment of autoimmune disorders. A desired improvement in efficacy and safety necessitate the development of alternate,…
Abstract Number: 0947 • ACR Convergence 2020
STING Gain-of-Function in Radio-resistant Cells Supports a Lymphocyte Dependent Auto-inflammatory Lung Disease
Kevin Gao¹, Mona Motwani¹, Ann Marshak-Rothstein² and Katherine Fitzgerald¹, ¹University of Massachusetts medical school, worcester, MA, ²University of Massachusetts medical school, Newton, MA
Background/Purpose: cGAS-STING is a cytosolic dsDNA sensing pathway whose regulation is vital to immune homeostasis. Pediatric patients with constitutively active STING mutations develop an autoinflammatory…
Abstract Number: 0991 • ACR Convergence 2020
Pathogenic, Glycolytic PD-1+ B Cells Accumulate in the Hypoxic RA Joint
Achilleas Floudas¹, Nuno Neto², Viviana Marzaioli³, Kieran Murray⁴, Barry Moran⁵, Michael Monaghan⁶, Candice Low⁷, Ronan Mullan⁸, Navin Rao⁹, Vinod Krishna⁹, Sunil Nagpal¹⁰, Douglas Veale¹¹ and Ursula Fearon³, ¹Molecular Rheumatology Trinity Biomedical Sciences Institute, Dublin, Dublin, Ireland, ²Department of Mechanical and Manufacturing Engineering, Dublin, Dublin, Ireland, ³Molecular Rheumatology, Trinity College Dublin, Dublin, Dublin, Ireland, ⁴Saint Vincent's University Hospital, Dublin 4, Dublin, Ireland, ⁵Trinity Biomedical Sciences Institute, Dublin, Ireland, ⁶Department of Mechanical and Manufacturing Engineering, Dublin, Ireland, ⁷EULAR Centre for Arthritis and Rheumatic diseases, St Vincents University Hospital, UCD, Dublin, Ireland, ⁸Adelaide and Meath Hospital, Dublin, Dublin, Ireland, ⁹Janssen R&D, Spring House, PA, ¹⁰Janssen Research & Development, Collegeville, PA, ¹¹EULAR Centre for Arthritis and Rheumatic Diseases, St Vincents University Hospital, UCD, Dublin, Dublin, Ireland
Background/Purpose: Rheumatoid arthritis (RA) often has a progressive and debilitating course, with significant impact on the patient’s quality of life. Despite the long-known association with…
Abstract Number: 0992 • ACR Convergence 2020
Impact of Selective Inhibitors of Nuclear Export on SLE Plasma Cells Is Modulated by the BM Microenvironment
Neha Nandedkar-Kulkarni¹, Nida Meednu², Jennifer Albrecht², Jennifer Barnas², Douglas Widman³ and Jennifer Anolik², ¹University of Rochester, Rochester, NY, ²University of Rochester Medical center, Rochester, NY, ³Karyopharm Therapeutics, Newton, MA
Background/Purpose: Systemic lupus erythematous (SLE) is a complex autoimmune disorder with heterogeneous disease presentation and a multi-pronged pathogenesis. Although autoreactive plasma cells play a key…
Abstract Number: 0994 • ACR Convergence 2020
Does Tofacitinib Impact B Cell Functions?
Guillaume Decarriere¹, Julie Mielle², Bernard Combe³, Jacques Morel¹, Rachel Audo² and Claire Daien¹, ¹Rheumatology department, CHU Montpellier and University of Montpellier, Montpellier, France, ²Institut de génétique moléculaire de Montpellier (IGMM), Montpellier, France, ³University of Montpellier, Montpellier, France
Background/Purpose: Tofacitinib (tofa) inhibits cytokine signaling mediated by JAK1 JAK3 pathways leading therefore to a decrease in Th17 and an increase of Treg cells. The…
Abstract Number: 0995 • ACR Convergence 2020
Jo-1-Binding B Cells Undergo Limited Class-Switching but Are Biased Towards Autoreactive-Prone and Memory B Cell Subsets in Anti-histidyl-tRNA Synthetase Syndrome
Jennifer Young-Glazer¹, Alberto Cisneros², Erin Wilfong¹, Scott Smith¹, Leslie J. Crofford¹ and Rachel Bonami¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbit University Medical Center, Nashville, TN
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are systemic autoimmune diseases traditionally classified as dermatomyositis or polymyositis, but these disorders are increasingly defined by the presence of…
Abstract Number: 0997 • ACR Convergence 2020
Novel Shared Antibody Specificities in Ro Antibody Negative Sjögren’s Syndrome
Sherri Longobardi¹, Constantin Georgescu², Christina Lawrence³, Charmaine Moya³, Jonathan Wren⁴, Judith James⁵, Kathy Sivils³ and A. Darise Farris⁶, ¹Graduate Program in Biological Sciences, University of Oklahoma Health Sciences Center; Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Genes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Genes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, ⁵Oklahoma Medical Research Foundation, Oklahoma City, ⁶Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City
Background/Purpose: Sjögren’s syndrome (SS) is a rheumatic autoimmune disease characterized by focal lymphocytic infiltrates in the lacrimal and salivary glands, severe dry mouth and eyes,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].